Syndicated Research Report Pharmaceuticals

Azilsartan Market

Size, Share & Industry Analysis, By Type (Azilsartan Tablets, Azilsartan Medoxomil Tablets), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Homecare), By Prescription Pattern (First-Line Therapy, Second-Line Therapy, Combination Therapy), By Therapeutic Approach (Monotherapy, Step-Up Therapy, Maximal Therapy), and Regional Forecast, 2026-2034

Report ID 24LS-15255
Pages 84
Last Updated
Author 24LifeSciences Research Team
Industry Pharmaceuticals
Starting from $995 USD

Market Overview

2025 Market SizeUSD 580 MnBase year
2026 EstimateUSD 605.2 MnEstimated year
2034 ForecastUSD 850 MnForecast value
CAGR4.3%2026–2034
Largest RegionNorth America2025

Azilsartan Market Overview

The global Azilsartan market was valued at USD 580 million in 2025 and is estimated at USD 605.2 million in 2026. The market is projected to reach USD 850 million by 2034, exhibiting a 4.3% CAGR during 2026–2034.

1.4 billionAdults aged 30–79 living with hypertension worldwide in 2024.WHO, 2025
23%Only about 23% of adults with hypertension globally had it controlled in 2024.WHO, 2025
40–80 mg2025 U.S. hypertension guideline lists azilsartan at 40–80 mg once daily.AHA/ACC, 2025
80 mg dailyCurrent U.S. azilsartan medoxomil labeling recommends 80 mg once daily for most adults.DailyMed, 2026

Azilsartan is an angiotensin II receptor blocker used to treat hypertension by selectively blocking the AT1 receptor and reducing angiotensin-II-mediated vasoconstriction and aldosterone effects. In the United States, the marketed oral product is azilsartan medoxomil, a prodrug rapidly converted to active azilsartan during absorption. Current labeling covers 40 mg and 80 mg tablets and permits use alone or with other antihypertensive agents.

The treatment base is large. WHO estimates that 1.4 billion adults aged 30–79 had hypertension in 2024, yet only about 23% had their blood pressure controlled. This persistent control gap creates demand for effective chronic oral therapy, including angiotensin receptor blockers. The 2025 U.S. high-blood-pressure guideline includes azilsartan among the ARB options at 40–80 mg once daily and emphasizes a general treatment goal below 130/80 mm Hg for most adults.

The market is increasingly influenced by generic competition and fixed-dose combinations. Lupin received the first U.S. generic approvals for azilsartan medoxomil 40 mg and 80 mg tablets in 2022. Alkem received first generic approval in January 2025 for azilsartan medoxomil/chlorthalidone 40/12.5 mg and 40/25 mg tablets, while the current single-agent NDA label was repackaged and marketed by Wilshire Pharmaceuticals beginning in April 2026. These changes improve availability but increase price competition around the original Edarbi franchise.

Key Takeaways

  • Market size and growth: The market is valued at USD 580 million in 2025 and is projected to reach USD 850 million by 2034, representing a 4.3% CAGR during 2026–2034.
  • Leading formulation: Azilsartan Tablets remain the dominant type, with azilsartan medoxomil 40 mg and 80 mg oral tablets representing the principal commercial presentations.
  • Leading distribution channel: Hospital Pharmacies remain the leading source-model channel, while retail and online pharmacy channels are increasingly important for chronic refill therapy.
  • Leading therapeutic approach: Step-Up Therapy is the dominant treatment pattern because antihypertensive therapy is adjusted or combined according to blood-pressure response and patient risk.
  • Regional leadership: North America is the largest regional market; the United States was approximately USD 210 million in 2025, while Asia-Pacific is the fastest-growing major region.
  • Competitive structure: Takeda remains the originator reference franchise, while Lupin, Jiangsu Hengrui, Cipla, Dr. Reddy's, Zydus, Teva, Aurobindo and other generic manufacturers increase price competition.

Report Scope & Market Segmentation

The study covers azilsartan and azilsartan-medoxomil oral products used in hypertension, preserving the source segmentation by formulation, distribution, end user, prescription pattern and therapeutic approach.

Report AttributeCoverage
Base Year2025
Estimated Year2026
Forecast Period2026–2034
Market MeasurementRevenue, USD million
By TypeAzilsartan Tablets; Azilsartan Medoxomil Tablets
By Application / DistributionHospital Pharmacy; Retail Pharmacy; Online Pharmacy; Others
By End UserHospitals; Specialty Clinics; Homecare
By Prescription PatternFirst-Line Therapy; Second-Line Therapy; Combination Therapy
By Therapeutic ApproachMonotherapy; Step-Up Therapy; Maximal Therapy
By Strength40 mg; 80 mg
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Key Market PlayersTakeda Pharmaceutical Company Limited; Lupin Limited; Jiangsu Hengrui Pharmaceuticals; Cipla Limited; Dr. Reddy's Laboratories; Zydus Lifesciences; Teva Pharmaceutical Industries; Aurobindo Pharma; Viatris; Sun Pharmaceutical Industries; Glenmark Pharmaceuticals; Torrent Pharmaceuticals; Wockhardt; Micro Labs; USV Private Limited; Wilshire Pharmaceuticals / Azurity; Alkem Laboratories

Azilsartan Market Dynamics

Large uncontrolled hypertension population sustains long-term demand

WHO reports 1.4 billion adults aged 30–79 with hypertension, with only about 320 million having the condition controlled. Chronic treatment need remains substantial across all major regions.

Guideline inclusion supports continued ARB use

The 2025 AHA/ACC guideline continues to list ARBs as a first-line antihypertensive class and includes azilsartan at 40–80 mg once daily. This supports its clinical relevance even in a crowded generic ARB market.

Generic competition lowers price and expands accessibility

Lupin's first single-agent U.S. generic approval and Alkem's 2025 first generic azilsartan/chlorthalidone approval illustrate increasing competition around the franchise. Lower prices can expand access but compress market value per prescription.

Older ARBs create strong substitution pressure

Losartan, valsartan, candesartan, telmisartan and olmesartan have broad generic availability and long clinical familiarity. Payers often favor lower-cost alternatives unless azilsartan's blood-pressure profile or patient response supports its use.

Pregnancy and renal-risk warnings constrain use in defined groups

Current U.S. labeling carries a boxed warning for fetal toxicity and warns about hypotension, impaired renal function and hyperkalemia in susceptible patients, requiring appropriate patient selection and monitoring.

Azilsartan Clinical & Hypertension Treatment Landscape

Azilsartan competes within the first-line ARB class and is used either alone or as part of combination antihypertensive therapy.

Clinical / Treatment ContextRole of AzilsartanMarket Relevance
Uncomplicated hypertensionOnce-daily ARB therapy when medication treatment is indicated.Largest broad treatment setting.
Stage 2 hypertensionCan be paired with another first-line agent, including a thiazide-like diuretic.Supports combination-therapy growth.
Patients intolerant of ACE inhibitorsARBs can be selected when ACE-inhibitor cough or other intolerance makes an ARB preferable.Maintains class-level demand.
Resistant / difficult-to-control hypertensionMay be used within multidrug regimens under specialist supervision.Important specialty-clinic niche.
Older adults / CKD-risk patientsRequires monitoring of renal function, potassium and volume status according to patient characteristics.Raises importance of individualized prescribing.

Azilsartan Market Segmentation by Type

Report Segmentation
By Type

Azilsartan Tablets form the broad commercial base, while Azilsartan Medoxomil Tablets are the principal prodrug formulation used in current U.S. products.

Leading Type

Azilsartan Tablets

The active-drug concept underpins the market and is widely recognized across regional formulations. Tablet dosing supports once-daily chronic hypertension management.

Key Prodrug Form

Azilsartan Medoxomil Tablets

Azilsartan medoxomil is converted to active azilsartan during absorption and is marketed in 40 mg and 80 mg strengths. Current U.S. labeling recommends 80 mg once daily for most adults.

Azilsartan Market Segmentation by Distribution Channel

Report Segmentation
By Application / Distribution

Hospital Pharmacy is the leading source-model channel, while retail and online channels provide most refill convenience for stable chronic patients.

Leading Channel

Hospital Pharmacy

Hospital pharmacies support treatment initiation, specialist prescribing and management of patients with cardiovascular or renal comorbidities.

Maintenance Channel

Retail Pharmacy

Retail pharmacies remain important for monthly or 90-day refills of chronic antihypertensive therapy and are central to generic substitution.

Fast-Growing Channel

Online Pharmacy

Mail-order and online pharmacy services reduce refill friction and can support long-term adherence in stable patients.

Other Channels

Others

Integrated delivery networks, specialty mail-order programs and regional government procurement can contribute depending on country structure.

Azilsartan Market Segmentation by End User

Report Segmentation
By End User

Hospitals form the largest institutional end-user segment in the source model, while specialty clinics and homecare support long-term chronic management.

Leading End User

Hospitals

Hospital and health-system physicians initiate or adjust therapy in patients with uncontrolled hypertension and comorbid cardiovascular or renal disease.

Specialist End User

Specialty Clinics

Cardiology and hypertension clinics manage difficult-to-control patients and multidrug regimens where selection among ARBs may be more individualized.

Largest Long-Term Setting

Homecare

Once treatment is stabilized, azilsartan is taken daily at home. Home blood-pressure monitoring and refill convenience therefore influence long-term persistence.

Azilsartan Market Segmentation by Prescription Pattern

Report Segmentation
By Prescription Pattern

Combination Therapy has the strongest growth potential, while first- and second-line use depend on payer policy, patient characteristics and physician preference among ARBs.

Established Use

First-Line Therapy

ARBs are first-line antihypertensive drugs in current U.S. guidance. Azilsartan competes with numerous lower-cost generic ARBs within this broad first-line category.

Selective Use

Second-Line Therapy

Azilsartan can be introduced when blood pressure remains uncontrolled or another agent is not tolerated, creating stable second-line demand.

Fastest-Growing Pattern

Combination Therapy

Single-pill and multi-pill combinations are increasingly used to reach guideline-recommended blood-pressure targets more rapidly, supporting azilsartan/chlorthalidone and other combination approaches.

Azilsartan Market Segmentation by Therapeutic Approach

Report Segmentation
By Therapeutic Approach

Step-Up Therapy is the dominant approach because antihypertensive treatment is progressively intensified according to blood-pressure response and overall cardiovascular risk.

Foundational Approach

Monotherapy

A single ARB may be sufficient for selected patients with less severe hypertension or when treatment is being initiated cautiously.

Leading Approach

Step-Up Therapy

Dose adjustment and addition of complementary antihypertensive classes are common when target blood pressure is not achieved, making step-up treatment the dominant practical pathway.

High-Intensity Approach

Maximal Therapy

Patients with resistant hypertension may require three or more drug classes and specialist monitoring. This segment is smaller but clinically complex.

Regional Market Analysis

North America

North America is the largest regional market. The United States was approximately USD 210 million in 2025 and has mature hypertension diagnosis, reimbursement and pharmacy distribution. Current FDA and DailyMed records confirm active marketing of 40 mg and 80 mg azilsartan medoxomil tablets.

Europe

Europe is a mature antihypertensive market with strong generic substitution and national price controls. Germany, France and the United Kingdom are major markets, although older ARBs with extensive generic competition can restrict azilsartan share.

Asia-Pacific

Asia-Pacific is the fastest-growing major region. WHO reported more than 273 million people with hypertension in South-East Asia in 2026, while China is projected to reach approximately USD 180 million in azilsartan market value by 2034. Japan also has long-standing familiarity with azilsartan-based therapy.

Latin America

Brazil, Mexico and other urban markets have large hypertension burdens and expanding generic access. Price sensitivity favors generics and fixed-dose combinations when reimbursed or competitively priced.

Middle East & Africa

GCC countries have strong chronic-disease treatment infrastructure, while broader African adoption is limited by diagnosis gaps, medicine availability and healthcare access. Hypertension control remains a major public-health priority across the region.

Guideline, Regulatory & Safety Environment

Azilsartan is an established prescription ARB with current regulatory, generic and guideline support, but its use remains shaped by class-wide safety precautions.

Regulatory / Clinical ElementCurrent PositionMarket Effect
Current U.S. labelAzilsartan medoxomil tablets are marketed in 40 mg and 80 mg strengths and are indicated for adult hypertension.Defines the core U.S. commercial market.
Recommended adult dose80 mg once daily for most adults; consider 40 mg in patients treated with high doses of diuretics.Supports 80 mg as the principal maintenance strength.
First single-agent genericLupin received first generic approval for 40 mg and 80 mg in July 2022.Introduced direct price competition.
First combination genericAlkem received first generic approval for azilsartan medoxomil/chlorthalidone in January 2025.Expands lower-cost fixed-dose combination access.
2025 AHA/ACC guidelineLists azilsartan 40–80 mg once daily among ARB options and favors two first-line agents for stage 2 hypertension when appropriate.Supports combination-therapy positioning.
Boxed warningCurrent labeling warns of fetal toxicity from renin-angiotensin system exposure.Restricts use during pregnancy.

Competitive Landscape

The market has shifted from a single-originator environment toward a more competitive generic landscape, with national and regional manufacturers using price, distribution and combination products to gain share.

Originator Franchise

Takeda Pharmaceutical Company

Takeda developed and launched Edarbi and remains associated with the originator molecule and manufacturing infrastructure. The core source model assigns the originator franchise the largest global share.

First U.S. Generic

Lupin

Lupin received first U.S. generic approvals for azilsartan medoxomil 40 mg and 80 mg tablets in July 2022, establishing a direct generic pathway for the single-agent product.

2025 Combination Entrant

Alkem Laboratories

Alkem received first generic approval for azilsartan medoxomil/chlorthalidone 40/12.5 mg and 40/25 mg tablets in January 2025 and qualified for 180-day exclusivity subject to statutory conditions.

Current U.S. NDA Labeler

Wilshire Pharmaceuticals / Azurity

DailyMed shows a current azilsartan medoxomil NDA label updated in April 2026 with 40 mg and 80 mg products marketed from April 27, 2026.

Regional Generic Competition

Jiangsu Hengrui, Cipla, Dr. Reddy's, Zydus, Teva, Aurobindo & Others

Generic manufacturers compete through local registrations, payer contracting, API integration and lower pricing across Asia, Latin America and other markets.

Key Companies Profiled

  • Takeda Pharmaceutical Company Limited
  • Lupin Limited
  • Jiangsu Hengrui Pharmaceuticals
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Zydus Lifesciences
  • Teva Pharmaceutical Industries
  • Aurobindo Pharma
  • Viatris
  • Sun Pharmaceutical Industries
  • Glenmark Pharmaceuticals
  • Torrent Pharmaceuticals
  • Wockhardt
  • Micro Labs
  • USV Private Limited
  • Wilshire Pharmaceuticals / Azurity
  • Alkem Laboratories

Recent Developments in the Azilsartan Market

27 April 2026: Wilshire Pharmaceuticals began marketing 40 mg and 80 mg azilsartan medoxomil tablets under NDA 200796, following a current DailyMed label update dated 20 April 2026.

17 May 2026: WHO's World Hypertension Day 2026 update reiterated that approximately 1.4 billion people live with hypertension globally and that only about one in four have adequate blood-pressure control.

21 January 2025: FDA granted first generic approval to Alkem Laboratories for azilsartan medoxomil/chlorthalidone tablets in 40/12.5 mg and 40/25 mg strengths.

14 August 2025: The 2025 AHA/ACC high-blood-pressure guideline was published, retaining ARBs as first-line antihypertensive agents and listing azilsartan at 40–80 mg once daily.

Market Outlook, 2026–2034

The global Azilsartan market is projected to grow from USD 605.2 million in 2026 to USD 850 million by 2034, at a 4.3% CAGR. Growth will be supported by the large uncontrolled hypertension population, combination therapy and improving generic access, while older low-cost ARBs and pricing pressure limit faster revenue expansion.

Forecast VariableCurrent DirectionExpected Effect Through 2034
Hypertension burden1.4 billion adults globally had hypertension in 2024.Sustains large long-term treatment demand.
Control gapOnly about 23% of affected adults had controlled blood pressure.Creates room for treatment intensification.
Generic penetrationSingle-agent and fixed-dose generic competition is expanding.Improves access but compresses price.
Combination therapyGuidelines support multi-drug treatment for stage 2 hypertension.Raises combination-product opportunity.
Asia-PacificLarge patient populations and improving medicine access support faster growth.Creates strongest incremental volume growth.

Report Coverage

The study supports cardiovascular portfolio strategy, generic-market planning, pharmacy-channel analysis, combination-product positioning and competitive benchmarking.

Market Sizing & Forecasting2025 base year, 2026 estimate and 2026–2034 global/regional outlook.
Segment AnalysisFormulation, distribution, end user, prescription pattern, therapeutic approach and strength.
Clinical LandscapeARB positioning, monotherapy, step-up treatment and combination therapy.
Regional AnalysisNorth America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Competitive IntelligenceTakeda, Lupin, Alkem, Wilshire/Azurity, Jiangsu Hengrui and generic manufacturers.
Regulatory & Guideline ReviewCurrent DailyMed labeling, FDA generic approvals and 2025 AHA/ACC hypertension guidance.

Research Methodology

Market sizing combines bottom-up product, supplier, procedure or prescription, and pricing analysis with top-down demand validation. Quantitative inputs include patient or procedure volumes, product mix, replacement or prescription cycles, end-user structure, regional access, pricing and adoption of newer technologies.

Primary research validates purchasing or prescribing criteria, clinical workflow, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional bodies, peer-reviewed literature and official manufacturer information. Forecast assumptions are cross-checked against demographics, treatment access, regulatory activity, product launches and regional healthcare capacity.

Forecasts incorporate global hypertension prevalence, treated and controlled patient populations, 40 mg versus 80 mg product mix, generic penetration, combination therapy, pharmacy channels, regional price levels and competition from other ARBs. North America remains the largest value market, while Asia-Pacific receives the strongest volume-growth assumptions.

Frequently Asked Questions

What is the global Azilsartan market size?

The market was valued at USD 580 million in 2025 and is estimated at USD 605.2 million in 2026. It is projected to reach USD 850 million by 2034, representing a 4.3% CAGR.

What is azilsartan used for?

Azilsartan is an angiotensin II receptor blocker used to treat hypertension and lower the risk associated with persistently elevated blood pressure.

What are the main azilsartan medoxomil strengths?

Current U.S. products are available as 40 mg and 80 mg tablets.

What is the recommended adult dose?

Current U.S. labeling recommends 80 mg once daily for most adults, with consideration of a 40 mg starting dose in patients receiving high-dose diuretics.

Which region leads the market?

North America is the largest regional market, while Asia-Pacific is the fastest-growing major region.

What is driving generic competition?

Lupin's first single-agent generic approval and Alkem's first azilsartan/chlorthalidone generic approval have expanded competition and lowered barriers to access.

Which companies are profiled?

The report profiles Takeda, Lupin, Jiangsu Hengrui, Cipla, Dr. Reddy's, Zydus, Teva, Aurobindo, Viatris, Sun Pharma, Glenmark, Torrent, Wockhardt, Micro Labs, USV, Wilshire/Azurity and Alkem.

What is the forecast period?

The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.

Research Sources & Evidence Base

View research sources used for this overview
  1. World Health Organization. 2025 global hypertension prevalence, treatment and control statistics.
  2. World Health Organization. World Hypertension Day 2026 global burden update.
  3. American Heart Association. 2025 high blood pressure guideline summary.
  4. AHA / Circulation. 2025 guideline including azilsartan 40–80 mg once-daily dosing table.
  5. DailyMed / U.S. National Library of Medicine. Current azilsartan medoxomil 40 mg and 80 mg U.S. prescribing information updated April 2026.
  6. U.S. Food and Drug Administration. First single-agent azilsartan medoxomil generic approval for Lupin.
  7. U.S. Food and Drug Administration. January 2025 first generic azilsartan medoxomil/chlorthalidone approval.
  8. U.S. Food and Drug Administration. Alkem ANDA approval and first-to-file exclusivity information.
  9. FDA Orange Book. May 2026 active azilsartan medoxomil 40 mg and 80 mg product listings.
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-15255
Base Year 2026
Forecast Period 2026–2034
Last Updated 14 Sep 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.